Abstract:
Techniques are provided for implementing a zone-based firewall policy. At a virtual network device, information is defined and stored that represents a security management zone for a virtual firewall policy comprising one or more common attributes of applications associated with the security zone. Information representing a firewall rule for the security zone is defined and comprises first conditions for matching common attributes of applications associated with the security zone and an action to be performed on application traffic. Parameters associated with the application traffic are received that are associated with properly provisioned virtual machines. A determination is made whether the application traffic parameters satisfy the conditions of the firewall rule and in response to determining that the conditions are satisfied, the action is performed.
Abstract:
The invention is a system for monitoring the status of a field device having data including a data acquisition module, a first and a second diagnosis engine, and a client having a user input element for receiving user input status.
Abstract:
A technique to send service period allocation from a network control point to a plurality of stations using an Announce frame of a 60 GHz DBand specification. The use of the Announce frame ensures that the control point receives confirmation of the service period allocation assigned to the stations before data transfer is permitted between the stations.
Abstract:
Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the mixture comprising the active agent and the polymer in at least two distinct stages.
Abstract:
An electronic blind and method for manufacturing an electronic blind, for whole or partial area light control management includes a pair of substrates, polymer/liquid crystal composite material sandwiched between the pair of substrates, and a pair of electrodes formed on an opposing surface of the pair of substrates. One electrode of the pair of electrodes is patterned over one substrate in line form at intervals from one side to the other side of the substrate, and an other electrode of the pair of electrodes is formed over the entire surface of another substrate.
Abstract:
A test controller implemented in an integrated circuit (IC) with partitioned scan chains provides enhanced control in performing scan tests. According to an aspect, a test controller can selectively control scan-in, scan-out and capture phases of scan tests for different scan chains of the IC to be independent. The number of pins required to interface the test controller with an external tester is less than the number of partitions that the test controller can support. According to another aspect, an IC includes a register corresponding to each partition to support transition fault (or LOS) testing. According to another aspect, an IC with partitioned scan chains includes serial to parallel and parallel to serial converters, thereby minimizing the external pins required to support scan tests.
Abstract:
This invention describes the discovery and synthesis of N-thiolated 2-oxazolidinones as a new class of anti bacterial agents. These compounds can be synthesized from 2-oxazolidinones by Ndeprotection and N-sulfenylation. These new substances were found to exhibit potent anti-bacterial activity, including bacteriostatic properties against Staphylococcus spp., including methicillin resistant Staphylcoccus aureus (MRSA), and Bacillus spp., including Bacillus anthracis.
Abstract:
Disclosed are compounds represented by structural formula (I): methods of producing compounds represented by structural formula (I). and their use in inhibiting oxidation in an oxidizable material.
Abstract:
The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.